Investors & Media

홈Investors & MediaNews release

News release

게시물 상세
News VasThera and KDDF sign agreement to advance drug discovery in South Korea
VasThera(alice.pak@vasthera.com)Date : 2022-11-04View : 133

VasThera and KDDF sign agreement to advance drug discovery in South Korea

 

VasThera  and the Korean Drug Development Fund (KDDF) have signed a project agreement to strengthen early phase clinical research in South Korea. 

VasThera and the Korean Drug Development Fund (KDDF) have signed a project agreement aimed at strengthening early phase clinical research in South Korea. 

A memorandum of understanding (MoU) has been signed by Vasthera and KDDF to provide drug development expertise and support for the emerging drug discovery and development industry in South Korea. 


The agreement will support a sharing of knowledge between KDDF and Celerion, providing the framework for collaborations of mutual benefit to both organisations. 

 

"Together with Celerion, KDDF will be able to provide professional consulting services to the Korean research communities to advance research activities and promote innovation." 

The collaboration will focus on developing innovative and efficient ways to bring Korean drug discoveries to the global market. It enhances both organisations’ ability to effectively apply principles of translational medicine to the development of innovative new drugs. 


KDDF funded companies will have access to Celerion’s extensive experience and expertise in early clinical research and bioanalysis, as well as the global footprint of external partner sites. Celerion will support all programmes with KDDF from the recently announced business expansion within the Biomedical Research Institute at Seoul National University Hospital, South Korea. 


KDDF CEO Dongho Lee said that the collaboration between KDDF and Celerion is for building effective partnerships between government, industry and academia. 

"Together with Celerion, KDDF will be able to provide professional consulting services to the Korean research communities to advance the research activities and promote important innovation," Lee said. 


 


Korea Drug Development Fund (KDDF), 

is a cross-ministry, full-cycle and government-initiated R & D business entity that supports new drug development beyond the boundaries of R & D. It was established by the Ministry of Science, ICT, and Future Planning, the Ministry of Trade, Industry, and Energy, and the Ministry of Health and Welfare to promote new drug development projects for global markets. Its aim is to have at least 10 new drugs developed and to advance the strategic investment platform for new drug R & D investment targeting global market. 


Prev
Next Dr. Sang Won Kang attended a business exchange meeting at the Korea Biotech Industry Organization
TOPTOP
검색 닫기